Skip to search formSkip to main contentSkip to account menu

CEV regimen

Known as: Cytoxan-Etoposide-Vincristine Regimen, VEC regimen 
A regimen consisting of cyclophosphamide, etoposide and vincristine used for the treatment of extensive-stage small cell lung cancer.
National Institutes of Health

Related topics

Related topics

9 relations

Broader (4)

Antineoplastic Combined Chemotherapy ProtocolsCarboplatinEtoposidecisplatin/cyclophosphamide/etoposide protocol
CyclophosphamideParaplatinSmall cell carcinoma of lungVincristine

Narrower (1)

VEJ regimen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.
Monoclonal antibodies that block the programmed death-1 (anti-PD-1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) immune… 
Review
2018
Review
2018
Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma
ABSTRACT Introduction: Current treatment of advanced melanoma is rapidly changing with the introduction of new and effective… 
2018
2018
Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity.
3092Background: Oncolytic viruses (OV) constitute a promising modality of cancer therapy. Intra-tumoral administration has… 
Review
2017
Review
2017
Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers.
Advanced liver cancers and biliary cancers represent diseases with dismal prognosis because of frequent local invasion and… 
Review
2016
Review
2016
The Role of Intralesional Therapies in Melanoma.
The US Food and Drug Administration has been rapidly approving new checkpoint inhibitors and targeted therapies for melanoma and… 
2015
2015
A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors
T-VEC, an intralesionally-delivered oncolytic immunotherapy, is a herpes simplex virus-1 engineered to selectively replicate in… 
2014
2014
New frontier in liver cancer treatment: Oncolytic viral therapy
Oncolytic viruses and active immunotherapeutics have complementary mechanisms of action (MOA) that are both self amplifying in… 
2013
2013
Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with…
3608^ Background: Pexa-Vec is an EGFR-targeted vaccinia virus engineered to express granulocyte-macrophage colony stimulating… 
Review
2012
Review
2012
An Examination of Measures Related to Children’s Exposure to Violence for Use by Both Practitioners and Researchers
Millions of children each year are exposed to violence in their homes, schools, and communities as both witnesses and victims. As… 
1983
1983
Comparative sequence and structure of different isolates of citrus exocortis viroid.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)